News

Amid growing investor interest in niche pharmaceutical service providers, Anthem Biosciences has come under the spotlight, with market expert Anil Singhvi identifying it as a potential long-term outperformer. Singhvi believes the company’s strong positioning in the Contract Research, Development and Manufacturing Organisation (CRDMO) space, backed by sound management and financial discipline, makes it an attractive portfolio candidate over the next two to three years.

Describing it as a “Vighnaharta stock”—a term he uses for companies capable of delivering stability and resilience—Singhvi argues that Anthem is well-placed to deliver meaningful returns, especially for investors with a medium- to long-term horizon.

Anthem’s core operations lie in the CRDMO segment—an area where pharmaceutical companies outsource critical research and production processes to specialised partners. With global pharma increasingly adopting asset-light models, demand for high-quality, reliable CRDMO services has grown steadily. Anthem has built a reputation for delivering across key stages of the drug lifecycle, including development and manufacturing support for several high-profile and blockbuster therapies.

Add Zee Business as a Preferred Source

Importantly, the company’s management team comprises industry veterans and professionals with deep operational experience, which Singhvi cites as one of its core strengths. “Execution matters more than scale in this space,” he noted.

On the financial front, Anthem has maintained positive cash flows, operates with minimal leverage, and demonstrates performance metrics that compare favourably with larger listed peers. While it may not match the scale of firms like Divi’s Laboratories, Singhvi believes the company holds its own on both efficiency and quality of operations.

“Size is just one metric. Anthem’s consistency and fundamentals are what stand out,” he added.

Despite the recent interest, market guru Singhvi maintains that Anthem’s current valuation remains reasonable, offering potential upside. He advises investors to consider accumulating the stock on dips—particularly if it corrects by around 10 per cent—and suggests using a systematic investment approach for better cost averaging.

For more risk-averse participants, incorporating a stop-loss strategy is recommended to mitigate potential downside in volatile market conditions.

Over a 1–3 year period, Singhvi has outlined price targets of Rs 1,100, Rs 1,300, and Rs 1,500, depending on broader market sentiment and company performance.

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

Senior Sub-editor at Zee Business English

shweta.shukla@India.com

Shweta Birendra Shukla is a journalist covering the stock market and corporate affairs, with prior stints at Business ...LATEST NEWSBy accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.